Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[As such, CALR first, followed by MPL if CALR is absent, mutation screening is appropriate in the diagnostic work-up of JAK2-unmutated ET but does not replace the need for BM morphologic examination in (1) confirming the diagnosis in triple-negative ET and (2) distinguishing ET from other myeloproliferative neoplasms that share the same mutations, including masked PV and early/prefibrotic myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[As such, CALR first, followed by MPL if CALR is absent, mutation screening is appropriate in the diagnostic work-up of JAK2-unmutated ET but does not replace the need for BM morphologic examination in (1) confirming the diagnosis in triple-negative ET and (2) distinguishing ET from other myeloproliferative neoplasms that share the same mutations, including masked PV and early/prefibrotic myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[As such, CALR first, followed by MPL if CALR is absent, mutation screening is appropriate in the diagnostic work-up of JAK2-unmutated ET but does not replace the need for BM morphologic examination in (1) confirming the diagnosis in triple-negative ET and (2) distinguishing ET from other myeloproliferative neoplasms that share the same mutations, including masked PV and early/prefibrotic myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[As such, CALR first, followed by MPL if CALR is absent, mutation screening is appropriate in the diagnostic work-up of JAK2-unmutated ET but does not replace the need for BM morphologic examination in (1) confirming the diagnosis in triple-negative ET and (2) distinguishing ET from other myeloproliferative neoplasms that share the same mutations, including masked PV and early/prefibrotic myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[As such, CALR first, followed by MPL if CALR is absent, mutation screening is appropriate in the diagnostic work-up of JAK2-unmutated ET but does not replace the need for BM morphologic examination in (1) confirming the diagnosis in triple-negative ET and (2) distinguishing ET from other myeloproliferative neoplasms that share the same mutations, including masked PV and early/prefibrotic myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[As such, CALR first, followed by MPL if CALR is absent, mutation screening is appropriate in the diagnostic work-up of JAK2-unmutated ET but does not replace the need for BM morphologic examination in (1) confirming the diagnosis in triple-negative ET and (2) distinguishing ET from other myeloproliferative neoplasms that share the same mutations, including masked PV and early/prefibrotic myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[As such, CALR first, followed by MPL if CALR is absent, mutation screening is appropriate in the diagnostic work-up of JAK2-unmutated ET but does not replace the need for BM morphologic examination in (1) confirming the diagnosis in triple-negative ET and (2) distinguishing ET from other myeloproliferative neoplasms that share the same mutations, including masked PV and early/prefibrotic myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[As such, CALR first, followed by MPL if CALR is absent, mutation screening is appropriate in the diagnostic work-up of JAK2-unmutated ET but does not replace the need for BM morphologic examination in (1) confirming the diagnosis in triple-negative ET and (2) distinguishing ET from other myeloproliferative neoplasms that share the same mutations, including masked PV and early/prefibrotic myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP1293935.RAUQ7v_BZOc3F9JnmaW8skO-D7qtjM9U5qhMX9qOTO6mw130_assertion description "[As such, CALR first, followed by MPL if CALR is absent, mutation screening is appropriate in the diagnostic work-up of JAK2-unmutated ET but does not replace the need for BM morphologic examination in (1) confirming the diagnosis in triple-negative ET and (2) distinguishing ET from other myeloproliferative neoplasms that share the same mutations, including masked PV and early/prefibrotic myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1293935.RAUQ7v_BZOc3F9JnmaW8skO-D7qtjM9U5qhMX9qOTO6mw130_provenance.
• NP1293937.RAVzVl5lbOTuYZS6muDPPHJr6fIAayRa_-xo4wervBTSo130_assertion description "[As such, CALR first, followed by MPL if CALR is absent, mutation screening is appropriate in the diagnostic work-up of JAK2-unmutated ET but does not replace the need for BM morphologic examination in (1) confirming the diagnosis in triple-negative ET and (2) distinguishing ET from other myeloproliferative neoplasms that share the same mutations, including masked PV and early/prefibrotic myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1293937.RAVzVl5lbOTuYZS6muDPPHJr6fIAayRa_-xo4wervBTSo130_provenance.
• NP1293941.RATieyl5oBfgsSf55mvEZIw4mC762a9BBrfdkbKH03IcQ130_assertion description "[As such, CALR first, followed by MPL if CALR is absent, mutation screening is appropriate in the diagnostic work-up of JAK2-unmutated ET but does not replace the need for BM morphologic examination in (1) confirming the diagnosis in triple-negative ET and (2) distinguishing ET from other myeloproliferative neoplasms that share the same mutations, including masked PV and early/prefibrotic myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1293941.RATieyl5oBfgsSf55mvEZIw4mC762a9BBrfdkbKH03IcQ130_provenance.
• NP1293936.RAqR2oF68shc_Bk0JCB1A3HsyE_rfFV5UM7WTfkSadEsE130_assertion description "[As such, CALR first, followed by MPL if CALR is absent, mutation screening is appropriate in the diagnostic work-up of JAK2-unmutated ET but does not replace the need for BM morphologic examination in (1) confirming the diagnosis in triple-negative ET and (2) distinguishing ET from other myeloproliferative neoplasms that share the same mutations, including masked PV and early/prefibrotic myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1293936.RAqR2oF68shc_Bk0JCB1A3HsyE_rfFV5UM7WTfkSadEsE130_provenance.
• NP1293938.RAhRzHOWtbMsC2sipXm0uuHsGTgz1cJ1xzUzCLvD4ctPY130_assertion description "[As such, CALR first, followed by MPL if CALR is absent, mutation screening is appropriate in the diagnostic work-up of JAK2-unmutated ET but does not replace the need for BM morphologic examination in (1) confirming the diagnosis in triple-negative ET and (2) distinguishing ET from other myeloproliferative neoplasms that share the same mutations, including masked PV and early/prefibrotic myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1293938.RAhRzHOWtbMsC2sipXm0uuHsGTgz1cJ1xzUzCLvD4ctPY130_provenance.
• NP1293933.RAHpQAc2442HKLy7LkBvS-ha8itBD1hsGvSU9YtS_mvZo130_assertion description "[As such, CALR first, followed by MPL if CALR is absent, mutation screening is appropriate in the diagnostic work-up of JAK2-unmutated ET but does not replace the need for BM morphologic examination in (1) confirming the diagnosis in triple-negative ET and (2) distinguishing ET from other myeloproliferative neoplasms that share the same mutations, including masked PV and early/prefibrotic myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1293933.RAHpQAc2442HKLy7LkBvS-ha8itBD1hsGvSU9YtS_mvZo130_provenance.
• NP1293940.RAE8s7vhNImsQq0Ov7NOMC8Widz6ULF_qQebUNPOHxeI4130_assertion description "[As such, CALR first, followed by MPL if CALR is absent, mutation screening is appropriate in the diagnostic work-up of JAK2-unmutated ET but does not replace the need for BM morphologic examination in (1) confirming the diagnosis in triple-negative ET and (2) distinguishing ET from other myeloproliferative neoplasms that share the same mutations, including masked PV and early/prefibrotic myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1293940.RAE8s7vhNImsQq0Ov7NOMC8Widz6ULF_qQebUNPOHxeI4130_provenance.
• NP1293943.RAP5rY4Gqx8QYqpP4xzOzeRJARNkZV8obc9OYTRyZ0NPQ130_assertion description "[As such, CALR first, followed by MPL if CALR is absent, mutation screening is appropriate in the diagnostic work-up of JAK2-unmutated ET but does not replace the need for BM morphologic examination in (1) confirming the diagnosis in triple-negative ET and (2) distinguishing ET from other myeloproliferative neoplasms that share the same mutations, including masked PV and early/prefibrotic myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1293943.RAP5rY4Gqx8QYqpP4xzOzeRJARNkZV8obc9OYTRyZ0NPQ130_provenance.
• NP1293939.RAywW0J9Ghb1UXfoQQTldQT5QKze_GszmkF8olEQyeUTM130_assertion description "[As such, CALR first, followed by MPL if CALR is absent, mutation screening is appropriate in the diagnostic work-up of JAK2-unmutated ET but does not replace the need for BM morphologic examination in (1) confirming the diagnosis in triple-negative ET and (2) distinguishing ET from other myeloproliferative neoplasms that share the same mutations, including masked PV and early/prefibrotic myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1293939.RAywW0J9Ghb1UXfoQQTldQT5QKze_GszmkF8olEQyeUTM130_provenance.